Clairvoyant has received regulatory approval for its Phase 2 trial investigating psilocybin for the treatment of alcohol use disorder (AUD).
The clinical trial, carried out by a wholly-owned subsidiary of Creso Pharma Limited, Halucenex Life Sciences Inc.,
MindMed has initiated a Phase 1 investigator-initiated trial led by collaborator Professor Dr Matthias Liechti at University Hospital Basel (UHB).
Chief clinical development officer of HMNC Brain Health, Hans Eriksson, speaks to Psychedelic Health about how the company’s formula, ‘Ketabon’, will provide the therapeutic benefits of ketamine without...
atai’s wholly owned subsidiary, EmpathBio, has received Medsafe central regulatory and The Health and Disability Ethics Committees (HDEC) ethics approvals to initiate a Phase 1 trial...
Origin Therapeutics’ portfolio company, Xpira Pharmaceuticals, has received FDA approval for its Psilocybin Trial IND Application.
Optimi Health Corp.
Results from a new study suggest that the antidepressant effects of ketamine can be prolonged in people with treatment-resistant depression through computer-based neurocognitive training.
Small Pharma has completed enrollment in its Phase 2a clinical trial of its intravenous formulation of DMT – candidate SPL026 – with psychotherapy for the treatment...
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has provided Mindset Pharma with Scientific Advice on a range of points to finalise its MSP-1014 clicnial...
